Drug intelligence / Profile preview

NSC Immunition

Development stage
Unknown
Lead developer
Nutritional Scientific Corporation
Administration
Oral
01

Overview

NSC Immunition is a dietary supplement developed by Nutritional Scientific Corporation (NSC) that features MG Beta 1,3/1,6 glucan as its primary active ingredient. Extracted from the cell walls of *Saccharomyces cerevisiae* (Baker's yeast), this purified isolate acts as a biological response modifier (BRM). It is designed to nutritionally support the immune system by activating and normalizing macrophages, dendritic cells, and other immune components. The product is marketed for a variety of health supports, including immune function, cardiovascular health, digestive health, and as a supportive aid for diabetes management. It is administered orally and is distinguished by its microparticulate formulation, which is intended to enhance potency compared to standard globular or reaggregated particulate glucan products.

Brand names
NSC ImmunitionImmunition NSC-24
Other names
Beta 1,3/1,6 glucanMG Beta 1,3/1,6 GlucanNSC-24NSC24NSC 24
02

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on NSC Immunition.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSC Immunition.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call